Iambic Therapeutics: $1.2B valuation, IPO Readiness 55, Series C. Iambic Therapeutics uses AI-assisted drug discovery combining molecular simulation, high-throughput virtual sc. Track live on The IPO Stack.
Iambic Therapeutics uses AI-assisted drug discovery combining molecular simulation, high-throughput virtual screening, and experimental validation to identify novel therapeutics for challenging diseases. Valued at $500M with $150M raised, Iambic has multiple discovery programs in oncology and rare diseases. Major AI biotech IPO candidate as AI-driven small molecule drug discovery accelerates through clinical validation and partnership deals with major pharma.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Iambic Therapeutics IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Iambic Therapeutics has not publicly announced IPO plans. Track TechStackIPO for the latest signals and subscribe to The IPO Stack for weekly updates.
Iambic Therapeutics is valued at $1.2B as of October 2022. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Accredited investors can access Iambic Therapeutics shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.
Iambic Therapeutics scores 55/100 (Grade: C) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Iambic Therapeutics has raised $263M in total venture capital and private equity funding, with backing from Andreessen Horowitz Bio, 8VC, Polaris Partners.
Iambic Therapeutics's notable investors include Andreessen Horowitz Bio, 8VC, Polaris Partners. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Iambic Therapeutics is a Biotechnology company. Iambic Therapeutics uses AI-assisted drug discovery combining molecular simulation, high-throughput virtual screening, a.